Elanco Animal Health Incorporated revenue by segment ELAN

Annual Quarterly

Elanco Animal Health Incorporated splits its revenue into 12 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Pet Health at $2.3 billion, 49% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018
Revenue	5,020	4,715	4,439	4,417	4,411	4,764	3,271	3,071	3,067
Pet Health	2,450 +11.2% share 48.8%	2,300 +7.3% share 48.8%	2,143 +1.9% share 48.3%	2,104 -1.6% share 47.6%	2,138 -9.0% share 48.5%	2,350 +73.0% share 49.3%	1,358 share 41.5%	—	—
Farm Animal	—	—	—	—	2,219 share 50.3%	—	1,835 share 56.1%	—	—
Cattle	1,214 +16.1% share 24.2%	1,125 +11.7% share 23.9%	1,007 +6.1% share 22.7%	949 share 21.5%	—	980 share 20.6%	—	—	—
Food Animal Ruminants And Swine	—	—	—	—	—	—	—	1,110 -5.4% share 36.2%	1,174 share 38.3%
Poultry	907 +12.7% share 18.1%	858 +7.8% share 18.2%	796 +4.1% share 17.9%	765 +6.8% share 17.3%	716 -3.8% share 16.2%	744 share 15.6%	—	—	—
Companion Animal Disease Prevention	—	—	—	—	—	—	—	788 share 25.7%	—
Food Animal Future Protein And Health	—	—	—	—	—	—	—	745 +4.8% share 24.3%	711 share 23.2%
Swine	387 +2.7% share 7.7%	379 +3.6% share 8.0%	366 -4.2% share 8.2%	382 -0.5% share 8.6%	384 -17.2% share 8.7%	464 share 9.7%	—	—	—
Companion Animal Therapeutics	—	—	—	—	—	—	—	348 +22.9% share 11.3%	283 share 9.2%
Aqua	—	—	81 -53.7% share 1.8%	175 +0.0% share 4.0%	175 +21.5% share 4.0%	144 share 3.0%	—	—	—
Product Category Strategic Exits	—	—	—	—	—	—	—	80 -15.1% share 2.6%	94 share 3.1%
Contract Manufacturing	62 +19.2% share 1.2%	53 +15.2% share 1.1%	46 +9.5% share 1.0%	42 -22.2% share 1.0%	54 -34.1% share 1.2%	82 +2.5% share 1.7%	80 +0.0% share 2.4%	80 share 2.6%	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ELAN (NYSE)
Fiscal year ends: December 31
Headquarters: Indianapolis, IN
SEC filer status: Large accelerated filer
SEC CIK: 1739104

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.